Healthcare of Ontario Pension Plan Trust Fund Makes New $20.47 Million Investment in Taysha Gene Therapies, Inc. $TSHA

Healthcare of Ontario Pension Plan Trust Fund purchased a new position in shares of Taysha Gene Therapies, Inc. (NASDAQ:TSHA) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 3,722,000 shares of the company’s stock, valued at approximately $20,471,000. Healthcare of Ontario Pension Plan Trust Fund owned approximately 1.36% of Taysha Gene Therapies as of its most recent filing with the SEC.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Marex Group plc bought a new position in shares of Taysha Gene Therapies during the 2nd quarter worth approximately $29,000. E Fund Management Co. Ltd. bought a new position in shares of Taysha Gene Therapies in the 2nd quarter worth $31,000. Arrowpoint Investment Partners Singapore Pte. Ltd. bought a new position in shares of Taysha Gene Therapies in the 3rd quarter worth $40,000. Tower Research Capital LLC TRC lifted its holdings in shares of Taysha Gene Therapies by 156.5% in the 2nd quarter. Tower Research Capital LLC TRC now owns 17,606 shares of the company’s stock worth $41,000 after purchasing an additional 10,742 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd lifted its holdings in shares of Taysha Gene Therapies by 143.8% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 7,811 shares of the company’s stock worth $43,000 after purchasing an additional 4,607 shares in the last quarter. 77.70% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts recently issued reports on the company. Wall Street Zen cut Taysha Gene Therapies from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Needham & Company LLC increased their target price on Taysha Gene Therapies from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Thursday, March 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Taysha Gene Therapies in a report on Friday, March 27th. Chardan Capital reiterated a “buy” rating and issued a $12.00 target price on shares of Taysha Gene Therapies in a report on Thursday, March 19th. Finally, Truist Financial upgraded Taysha Gene Therapies to a “strong-buy” rating in a report on Wednesday, March 25th. Two analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $11.64.

Insider Buying and Selling

In related news, insider Sukumar Nagendran sold 200,000 shares of the stock in a transaction on Friday, April 10th. The stock was sold at an average price of $4.46, for a total value of $892,000.00. Following the completion of the sale, the insider directly owned 1,136,410 shares of the company’s stock, valued at approximately $5,068,388.60. This represents a 14.97% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 3.78% of the company’s stock.

Taysha Gene Therapies Trading Up 4.6%

NASDAQ TSHA opened at $5.97 on Tuesday. The firm has a market capitalization of $1.72 billion, a P/E ratio of -15.71 and a beta of 1.19. The business has a fifty day simple moving average of $5.80 and a 200 day simple moving average of $5.19. Taysha Gene Therapies, Inc. has a 12 month low of $2.25 and a 12 month high of $7.30. The company has a current ratio of 14.04, a quick ratio of 14.04 and a debt-to-equity ratio of 0.23.

Taysha Gene Therapies (NASDAQ:TSHA) last released its quarterly earnings results on Wednesday, May 6th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.10) by ($0.02). On average, analysts predict that Taysha Gene Therapies, Inc. will post -0.5 EPS for the current fiscal year.

About Taysha Gene Therapies

Taysha Gene Therapies, Inc (NASDAQ: TSHA) is a clinical-stage biotechnology company focused on developing gene therapies for rare monogenic diseases of the central nervous system. Using a proprietary adeno-associated viral (AAV) vector platform, the company engineers novel capsids and regulatory elements to optimize delivery and expression of therapeutic genes. Its pipeline features lead programs such as TSHA-102 for GM2 gangliosidoses (Tay–Sachs and Sandhoff diseases), TSHA-101 for GM1 gangliosidosis and TSHA-103 for aromatic l-amino acid decarboxylase (AADC) deficiency, alongside earlier-stage candidates targeting other life-threatening pediatric CNS disorders.

Founded in 2019 and headquartered in Dallas, Texas, Taysha Gene Therapies completed its initial public offering in May 2021.